American Heart Journal
Volume 158, Issue 4 , Pages 592-598.e1 , October 2009

Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents

  • Dennis T. Ko, MD, MSc

      Affiliations

    • Division of Cardiology, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Dennis T. Ko, MD, MSc, Institute for Clinical Evaluative Sciences G1-06, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5.
    • ,
  • Maria Chiu, MSc

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Helen Guo, MSc

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Peter C. Austin, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Jean-François Marquis, MD

      Affiliations

    • University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    • ,
  • Jack V. Tu, MD, PhD

      Affiliations

    • Division of Cardiology, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada

Received 18 March 2009 ,Accepted 10 June 2009.

References 

  1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  2. Daemen J, Serruys PW. Drug-eluting stent update 2007: part II: unsettled issues. Circulation. 2007;116:961–968
  3. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745–754
  4. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130[see comment]
  5. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  6. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813–818
  7. Love MP, Schampaert E, Cohen EA, et al. The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Can J Cardiol. 2007;23:121–123
  8. Ho PM, Fihn SD, Wang L, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J. 2007;154:846–851
  9. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–2809
  10. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028–1036
  11. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–467
  12. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116
  13. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  14. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532–539
  15. Ko DT, Chiu M, Austin PC, et al. Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis. Am Heart J. 2008;156:125–134
  16. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393–1402
  17. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–186
  18. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331–342
  19. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458–1462
  20. Tseng CW, Brook RH, Keeler E, et al. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952–960
  21. Berkowitz SA, Gerstenblith G, Anderson GF. Medicare prescription drug coverage gap: navigating the “doughnut hole” with patients. JAMA. 2007;297:868–870
  22. Schneeweiss S, Patrick AR, Maclure M, et al. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007;115:2128–2135
  23. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61–69
  24. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–461

PII: S0002-8703(09)00543-2

doi: 10.1016/j.ahj.2009.06.030

American Heart Journal
Volume 158, Issue 4 , Pages 592-598.e1 , October 2009

Article Tools

* Image Usage & Resolution